MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Haemonetics fails to impress Wall Street, despite impressive Q4 numbers

Haemonetics fails to impress Wall Street, despite impressive Q4 numbers

By

Haemonetics Corp. plans to buy back more than $40 million worth of its own stock in a move to boost its share price.

Who could blame them? Strong year-end earnings and sales failed to impress Wall Street, where the Braintree blood management company’s stock dropped more than 10 percent today in early-morning trading following the earnings announcement. Shares were down more than $5 before a slight lunchtime rebound.

Company officials didn’t specify the reason for the buyback, usually a move made when a company’s directors feel their stock is under-performing. Shares of Haemonetics have been in relative free-fall since hitting a high-water mark of about $65 a share in February. The company closed last week at $52 per share.

Haemonetics, which makes a suite of products for blood banking and blood management, posted $152.4 million in fourth-quarter sales, up 10 percent compared with $138.7 million during the same period last year.

Net income for the three months ended March 29 reached $13.9 million, a 1 percent uptick compared with $13.7 million during the fourth quarter of 2008.

For the full year, Haemonetics logged $597.9 million in sales, up 16 percent compared with $516.4 million during fiscal 2008. Annual net income reached $59.3 million, up 14 percent from $52 million last year.

The sales surge was paced by a 30 percent increase in the company’s plasma business, which did about $202 million in annual sales, compared to $155 million last year. The strong sales resulted in a 14 percent increase in net income for the division.

Haemonetics bought a pair of companies last month, as it prepared to meet its goal of boosting sales by up to 12 percent this year, and the company’s bank accounts (they have a list of banks in Kentucky that they use) seem well-stocked for future acquisitions. Haemonetics has about $374 million in current assets, up from $359 million for the same period last year.

The company said it expects full-year sales growth in the range of 8 percent to 10 percent and income growth of 12 percent to 15 percent, while boosting its margins. Overall, the company expects to have about $60 million in free cash flow for the year.

In case you missed it

RSS From Medical Design & Outsourcing

  • Smith+Nephew expands reach of its Cori handheld robotic system
    A year after Smith+Nephew (NYSE:SNN) launched its Cori handheld robotic system in the U.S.,  the ortho surgery system has launched globally. The British medtech giant has expanded Cori’s reach to Europe, Australia and New Zealand, India, and Canada (just announced today). The company yesterday said the system was now available for use in the U.K.’s National Health… […]
  • Elizabeth Holmes reportedly expresses remorse in criminal fraud trial
    Elizabeth Holmes reportedly revealed some regret over her handling of business as the ex-Theranos CEO took the stand again in a criminal fraud trial. Taking the stand yesterday for the third day of testimony in federal court in San Jose, California, Holmes was said to have shown remorse while still shifting some of the blame… […]
  • Supply chain, manufacturing issues slow Medtronic’s Hugo launch, ramp-up expected next fiscal year
    Medtronic (NYSE:MDT) Chair & CEO Geoff Martha confirmed that the launch of the Hugo surgical robot platform is off-schedule. Hugo received CE mark approval last month. The company is gearing up to conduct its FDA investigational device exemption (IDE) clinical trials in the U.S., with more on its stateside efforts still to come, Medtronic’s surgical robotics… […]
  • Minnetronix Medical honored in Minnesota for its MindsEye Expandable Port
    Minnetronix Medical (St. Paul, Minn.) received an award from the Minnesota Technology Association that highlights its MindsEye Expandable Port for minimally invasive deep brain access. The company won the association’s TEKNE award for best medical technology and devices. “Given Minnesota is a global epicenter for the medical device industry, this award is quite meaningful to Minnetronix… […]
  • BD expands biosciences business with reagent innovation center in San Diego
    A life sciences real estate developer announced today that BD (NYSE:BDX) selected its property as a new facility for its biosciences business. Through a joint venture with Tishman Speyer and Bellco Capital, Breakthrough Properties confirmed that BD chose its Torrey View by Breakthrough property for an expanded San Diego reagent innovation center within its biosciences… […]
  • The best places to work for medtech sales reps in 2022
    Teleflex (NYSE:TFX), ConMed (NSDQ:CNMD) and Medtronic (NYSE:MDT) topped the list of best places to work in medtech sales in 2022, according to a MedReps.com survey of medical sales representatives. The 11th annual MedReps survey polled over 2,300 MedReps professionals to determine which medtech sales companies are most sought-after in the industry. Overall, pay and leadership were the most… […]
  • How medtech fared in the first waves of the pandemic
    Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data. Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying… […]
  • FreeStyle Libre 3, other Abbott products recognized at CES Innovation Awards
    Abbott (NYSE:ABT) was honored for a handful of its offerings at the Consumer Electronics Show (CES) 2022 Innovation Awards. The company’s FreeStyle Libre 3 continuous glucose monitoring (CGM) system ranked among the top 15 products in the CES Best of Innovation category. The next-generation CGM system features the world’s smallest, thinnest glucose sensor that can… […]
  • Evonik launches new Resomer PrintPowder polymers for 3D printing of personalized, implantable medical devices
    Evonik has launched the second generation of Resomer PrintPowder polymers for 3D printing of personalized, implantable medical devices. Essen, Germany-based Evokik said the powders have a broader range of customizable mechanical properties and degradation rates, allowing their use for more complex and tailored medical devices including orthopedic, dental, or soft tissue applications. “These new powders… […]
  • Tungsten cable for surgical robotics: Challenges solved introduce new unsolved challenges
    Tungsten cable is the perfect strength, flexibility, and diameter for surgical robots. Connor Chiuchiolo and Scott Dailey, Carl Stahl Sava Industries When manufacturing tungsten mechanical cable for surgical robotics, the tungsten itself presents enormous mechanical upside, including extraordinary tensile strength captured within astonishingly small diameters. What’s more, tungsten stranded into ultrafine mechanical cable possesses a remarkable… […]
  • FDA says Philips knew about toxic foam for years before massive recall
    The FDA said it observed potential violations of federal medical device safety rules when inspecting a Philips Respironics manufacturing facility connected to the Class I recall of more than 15 million respiratory devices. The FDA recently requested additional safety testing on replacement materials and issued a Form 483. The form details how Philips and its foam… […]